Suven Life Sciences secures product patents in India, South Korea

20 Feb 2018 Evaluate

Suven Life Sciences has secured one product patent from India and one product patent from South Korea corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029 and 2033 respectively.

The granted claims of the patents include the class of selective Alpha4 Beta2 and 5-HT4 compounds respectively and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Suven Life Sciences Share Price

166.95 0.10 (0.06%)
01-Jan-2026 10:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1712.55
Dr. Reddys Lab 1254.70
Cipla 1503.65
Zydus Lifesciences 908.85
Lupin 2084.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×